Select Page

We move prostate cancer diagnostic forward

Cambridge Oncometrix

Biomarker discovery and validation company

PROSTATE CANCER RISK STRATIFICATION TEST

Prostate cancer is one of the most frequent cancers globally. 1 out of 8 men will develop prostate cancer once in their lifetime. High incidence of the disease makes a reliable early diagnostic vital for better treatment outcomes. Current prostate cancer detection pathway is still very inaccurate and leads in over half of the cases to unnecessary prostate biopsies, where no cancer is found.

Cambridge Oncometrix has developed a revolutionary non-invasive pre-biopsy diagnostic test that allows for much-improved prostate cancer risk assessment in primary and secondary care.

OUR MISSION

Cambridge Oncometrix test will aid identification of men suspected of prostate cancer who can safely forgo prostate biopsy. We aim to reduce the number of unnecessary prostate biopsies by 50%.

Our test will:

 

  • Reduce the number of prostate biopsies
  • Save lives through earlier prostate cancer detection
  • Decrease healthcare costs
  • Improve patient experience and treatment outcomes

Oncometrix biomarkers within cancer cells

Early detection

OUR journey

AWARD WINNING

FUNDED BY

For more information contact us